Pemvidutide vs Tirzepatide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: ALT-801
Pemvidutide is Altimmune's once-weekly GLP-1/glucagon dual agonist, now being developed mainly for MASH (fatty liver disease with inflammation, formerly called NASH). It cleared fat out of the liver fast in trials and earned FDA Breakthrough Therapy designation, and its phase 3 trial (PERFORMA) started in August 2026. It also produced decent weight loss in an obesity trial, but it is not approved anywhere and its biggest phase 2 MASH trial missed on the fibrosis endpoint at 24 weeks.
Also: Mounjaro, Zepbound
Tirzepatide is a single peptide that activates two receptors at once: GIP and GLP-1, the two main incretin hormones your gut releases after eating. It is FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and obstructive sleep apnea, and it has produced the largest weight-loss numbers of any approved drug to date. Like semaglutide, this is a heavily trialed, fully approved medicine, not a gray-market research compound.
Key Comparison Insights
- Tirzepatide is FDA approved, while Pemvidutide remains in research stages.
- Pemvidutide is categorized as Metabolic, while Tirzepatide is Weight Loss.
- Tirzepatide has stronger research evidence (FDA Approved) compared to Pemvidutide (Human Trials).
Detailed Comparison
| Attribute | Pemvidutide | Tirzepatide |
|---|---|---|
| Category | Metabolic | Weight Loss |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Pemvidutide activates two receptors in roughly balanced fashion. The GLP-1 side cuts appetite and slows stomach emptying, like semaglutide. The glucagon side acts directly on the liver, pushing it to burn fat and raising energy expenditure, which is why this drug class is especially interesting for fatty liver. Altimmune attaches its EuPort domain to stretch the half-life for weekly dosing and, the company says, to slow absorption for better tolerability. Glucagon activity can raise blood sugar on its own, so balancing the two signals is the design challenge. Most of the mechanism story comes from the company and is plausible, but independent data are limited. | Tirzepatide is a dual agonist, meaning it switches on both the GIP receptor and the GLP-1 receptor with one molecule. GLP-1 activation boosts glucose-dependent insulin release, suppresses glucagon, slows gastric emptying, and reduces appetite through the brain. Adding GIP activation appears to enhance insulin response and improve how fat tissue handles energy, and the combination seems to outperform hitting GLP-1 alone. As with semaglutide, the peptide carries a fatty-acid chain that binds albumin to extend its half-life enough for once-weekly dosing. The exact reason the GIP arm adds so much benefit is still being worked out, but the clinical effect of combining the two is clear. |
| Common Dosing | 1.2-1.8 mg once weekly (MASH trial doses) Once weekly | 5-15 mg weekly (after titration) Once weekly |
| Administration | Subcutaneous injection once weekly | Subcutaneous injection weekly |
| Typical Duration | 24-48 weeks in completed trials; phase 3 runs 52 weeks for the biopsy endpoint and years for outcomes | Long-term / chronic use |
| Best Time to Take | Same day each week | Morning, same day each week |
Possible Side Effects May vary by individual |
|
|
| Research Summary | In the phase 2 MOMENTUM obesity trial (391 adults without diabetes, 48 weeks), the 2.4 mg weekly dose produced 15.6% mean weight loss versus 2.2% on placebo, and a small MRI sub-study (50 people) found about 78% of the weight lost was fat. The focus then shifted to MASH. The phase 2b IMPACT trial randomized 212 people with biopsy-confirmed MASH and F2-F3 fibrosis to 1.2 mg, 1.8 mg or placebo. At 24 weeks, MASH resolution was 59.1% and 52.1% versus 19.1% on placebo, a strong result. But fibrosis improvement (31.8% and 34.5% versus 25.9%) was not statistically significant, and the stock fell by more than half on the news in June 2025. The 48-week data (December 2025) showed significant improvements in non-invasive fibrosis markers (ELF score and liver stiffness) and continued weight loss without a plateau, with fewer dropouts for side effects than placebo. The PERFORMA phase 3 trial (about 1,790 people, titrating to 1.8 or 2.4 mg) began in August 2026, with a 52-week biopsy readout expected in 2029. A separate phase 2 trial in alcohol use disorder (RECLAIM) reported positive topline results in July 2026. Bottom line: strong on liver fat and MASH resolution, still unproven on the fibrosis outcomes regulators care most about. | The trial evidence is strong and recent. In SURMOUNT-1 (New England Journal of Medicine, 2022), adults with obesity but without diabetes lost an average of 22.5% of body weight on the 15 mg dose over 72 weeks, versus 2.4% on placebo, with about 9 in 10 participants losing weight. In a head-to-head trial, SURMOUNT-5 (2025), tirzepatide produced roughly 20% weight loss versus about 14% for semaglutide. The SURPASS diabetes program showed strong HbA1c reductions, and a large cardiovascular outcomes trial supported its safety profile. Side effects mirror other incretin drugs: mostly nausea, diarrhea, and other gastrointestinal issues, generally worst during dose titration. These are large, randomized, peer-reviewed trials, putting tirzepatide among the best-evidenced metabolic drugs available. |
Frequently Asked Questions: Pemvidutide vs Tirzepatide
What is the difference between Pemvidutide and Tirzepatide?
Pemvidutide is a metabolic peptide that pemvidutide is altimmune's once-weekly glp-1/glucagon dual agonist, now being developed mainly for mash (fatty liver disease with inflammation, formerly called nash). it cleared fat out of the liver fast in trials and earned fda breakthrough therapy designation, and its phase 3 trial (performa) started in august 2026. it also produced decent weight loss in an obesity trial, but it is not approved anywhere and its biggest phase 2 mash trial missed on the fibrosis endpoint at 24 weeks. Tirzepatide is a weight loss peptide that tirzepatide is a single peptide that activates two receptors at once: gip and glp-1, the two main incretin hormones your gut releases after eating. it is fda-approved as mounjaro for type 2 diabetes and as zepbound for chronic weight management and obstructive sleep apnea, and it has produced the largest weight-loss numbers of any approved drug to date. like semaglutide, this is a heavily trialed, fully approved medicine, not a gray-market research compound. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Pemvidutide or Tirzepatide?
Neither is universally "better" - the choice depends on your specific goals. Pemvidutide is typically used for metabolic purposes, while Tirzepatide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Pemvidutide and Tirzepatide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Pemvidutide and Tirzepatide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.